Table 1.
Baseline epidemiologic measures and 5-year impact of IPT
| Outcome | Baseline* | Five-year projections under varying IPT coverage |
|||
|---|---|---|---|---|---|
| 0% | 33% | 66% | 99% | ||
| TB prevalence per 100,000 people | 252 | 779 | 675 | 496 | 190 |
| Proportion of population with latent infection, % | 34.5 | 37.4 | 34.1 | 28.6 | 19.8 |
| Proportion of TB that is drug-resistant, % | 4.0 | 4.9 | 5.3 | 6.4 | 12.7 |
| Prevalence of drug-resistant TB per 100,000 people | 10 | 38 | 36 | 32 | 24 |
| Proportion of population HIV-infected, % | 16.3 | 33.5 | 34.4 | 36.1 | 39.6 |
| Percent reduction in cumulative HIV deaths (years 0–5) attributable to IPT, % | — | Reference† | 3.5 | 9.6 | 21.2 |
*Baseline = year 0 = time IPT was introduced.
†Baseline no. of cumulative HIV deaths (years 0–5) when IPT coverage = 0% (number of deaths to which increased levels of IPT coverage were compared).